Fin Cascade

Prices as of 20 Nov 2026 close · Not investment advice

Updated 21 Nov, 21:20 IST

Sudarshan Pharma Industries Limited

NSE: SUDARSHAN · Specialty Chemicals

Share price ₹29.90

down 3.36% · close of 20 Nov 2026

Business scoreHow strong the business is, in one number.Changed 20 Nov 2026How it was built →

Your ratios

Market cap

₹761 Cr

P/E ratio

26.2

EPS TTM to Sep 2026

P/B ratio

3.9

ROCE

15.2%

ROE

16.3%

Dividend yield

0.0%

as of 20 Nov 2026

Profit checks6/8 clear

1 · Overview

Overview

Price, valuation, sales and profit over the range you pick. Prices as of the last close; results as filed.

Up candleDown candle
Volume, average a day
Latest
16 Nov – 20 Nov 2026
Open₹33.80
High₹33.80
Low₹28.51
Close₹29.90
Change on the week−8.59%
50 DMA₹36.04
200 DMA₹33.30
Avg volume a day49.7k
Return · 1Yr
+28.93%
₹23.19 → ₹29.90
From the 1Yr high
−29.33%
High ₹42.31 · 21 Jul 2026
From the 1Yr low
+55.49%
Low ₹19.23 · 27 Jan 2026
From the 200 DMA
−10.21%
200 DMA ₹33.30

One candle a week · body: open to close, green when it closed higher · line: high to low

At a glance · 1Yr

Every small chart follows the range above. Point at it to read a value; click it to open it.
P/E
26.2
1Yr range 23.8 – 46.8
Nov 2025 – Nov 2026
Revenue (sales)
₹217 Cr
Sep 2026 · +28.48% on a year ago
Sep 2025 – Sep 2026 · 5 quarters
Operating margin
9.5%
average 7.9% · low 5.5% · high 9.5%
Sep 2025 – Sep 2026 · 5 quarters
Net profit
₹7.78 Cr
Sep 2026 · +101.04% on a year ago
Sep 2025 – Sep 2026 · 5 quarters
EPS (yearly)
₹0.97
FY26 · +46.97% on FY25
FY23 – FY26 · 4 years
ROCE (yearly)
15%
FY26 · average 15% over 1 year
FY26 – FY26 · 1 year (all we have)
Free cash flow (yearly)
−₹50.8 Cr
FY26 · -218% of net profit
FY26 – FY26 · 1 year (all we have)
Promoter holding
57.81%
FII 21.9% · +0.42 pts in a year
Sep 2025 – Sep 2026 · 5 quarters

2 · Results

Latest result · Q2 FY27

What the last results showed. Whether management kept its word is in Pro.

Net profit ₹7.78 Cr, up 101.0% on Sep 2025

Announced 29 Oct 2026 · Consolidated · Unaudited

Sales₹217 Crup 28.5% on Sep 2025
Operating profit₹20.6 Crup 123.6% on Sep 2025
Operating margin9.5%up 4.0 pts from 5.5%
Net profit₹7.78 Crup 101.0% on Sep 2025
Net margin3.6%up 1.3 pts from 2.3%
EPS₹0.31up 82.4% on Sep 2025
Sales, last 8 quarters ₹ crore
Show
Consolidated
Sales, operating profit and net profit, ₹ crore: 7 years to Mar 2026, then the last 12 months (the fainter bars).
TTMLast 12 months to Sep 2026
Sales₹780.32 Cr
Operating profit₹67.56 Cr8.7% of sales
Net profit₹28.94 Cr3.7% of sales
P/E26.2On 20 Nov 2026
Inside each sales bar: operating profit, and inside that, net profit.OPM: operating profit as % of sales. NPM: net profit as % of sales. Dashed line: the median of the P/E values shown (26.7)P/E on the last trading day of each period: that day's share price ÷ the 12-month earnings per share published by then. Blank where none is on record.

7 years, Mar 2020 to Mar 2026, and the last 12 months · key lines

Yearly profit and loss, 7 years, Mar 2020 to Mar 2026, and the last 12 months
LineMar 2020FY20Mar 2021FY21Mar 2022FY22Mar 2023FY23Mar 2024FY24Mar 2025FY25Mar 2026FY26TTMto Sep 2026
Sales₹ crore148.00193.00change on a year before +30%357.00change on a year before +85%461.00change on a year before +29%464.00change on a year before +1%505.04change on a year before +9%703.06780.32change on a year before +32%
Operating profit₹ crore5.007.00change on a year before +40%11.00change on a year before +57%15.00change on a year before +36%23.00change on a year before +53%40.00change on a year before +74%51.3267.56change on a year before +53%
Operating margin% of sales3.20%3.70%3.10%3.20%4.90%8.00%7.30%8.66%
Other income₹ crore0.000.000.001.003.000.008.718.80
Net profit₹ crore1.003.00change on a year before +200%5.00change on a year before +67%7.00change on a year before +40%11.00change on a year before +57%16.00change on a year before +45%23.3728.94change on a year before +60%
EPS₹ per share0.070.16change on a year before +129%0.31change on a year before +94%0.29change on a year before -6%0.48change on a year before +66%0.66change on a year before +38%0.971.17change on a year before +52%
Dividend paid out% of net profit0.00%0.00%0.00%10.00%0.00%0.00%0.00%

Small figure: change on the year before (TTM: on the 12 months to Sep 2025). TTM = the four quarters to Sep 2026. Lines that are 0 or blank in every column are not shown.

Sales and profit: growth a year, compounded, to Mar 2026; TTM is the last 12 months. Share price: to the latest close. A span can cross a demerger or an acquisition.

Sales

a year, compounded

5 years
30%
3 years
15%
TTM
32%

Profit

a year, compounded

5 years
54%
3 years
48%
TTM
45%

Share price

a year, compounded

3 years
56%
1 year
29%

Return on equity

average over the span

5 years
14%
3 years
14%
Last year
16%

3 · Quality & value

Answers

The questions investors ask most, each answered first in one line, then shown. From the company's own numbers.

How fast it has been growing

Fewer than three years of filings — too early to judge growth.

Whether it grew faster than its sector

It grew 15.1% a year against a sector median of 1.7% — 13.4 percentage points faster.

SUDARSHAN15.1% a year
Sector median1.7% a year

Room to re-rate, or risk of de-rating

At 26.2× earnings against a market that pays 23.0× across 2,280 companies we can price.

SUDARSHAN now26.2×
Its industry (5)56.4×
All 2,280 priced23.0×
Its own 5-year median33.3×

Its own industry sits at 56.4×, across 5 companies. It is against its own five-year median of 33.3×, the 16th percentile of its own range.

Whether growth justifies the valuation

Priced at 0.5 times its growth rate, on earnings growth of 47.8%.

SUDARSHAN · 26.2× ÷ 47.8%₹0.55
Gujarat Fluorochemicals Limited · 78.3× ÷ -23.6%—
Navin Fluorine International Limited · 56.4× ÷ 22.1%₹2.5
Aether Industries Limited · 85.3× ÷ 20.3%₹4.2
Deepak Nitrite Limited · 19.5× ÷ -12.8%—
Fine Organic Industries Limited · 34.9× ÷ -12.7%—

P/E ÷ profit growth a year (3 years). A dash: no profit growth to divide by.

How it compares with its peers

Against companies the exchange files under the same label (Specialty Chemicals), it ranks 29 of 79 on returns, 58 of 78 on margin.

Returns on capital29 of 79
Margin58 of 78

A longer bar is a better rank.

What makes it hard to beat — and is that still true?

A narrow advantage: it earns 15.2% on capital, ahead of 63% of companies filed under the same label.

Return on capital15.2%
Ahead of63% of peers

Whether its growth pays for itself

No — Over the last five years the business itself consumed ₹61 crore of cash before any plant spend, funded mostly borrowed — borrowings rose from ₹31 crore to ₹285 crore.

And the profit is not backed by cash: it reported a profit over 7 years and consumed cash from the business. Its cash comes back faster than it used to: it went from waiting 27 days for its cash to waiting 17 days for its cash.

Peers here are the 79 companies the exchange files under the same label (Specialty Chemicals). That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Business score & profit checks

How strong the business is, and whether its profit is real cash. Facts only, not advice.

Business score

62 out of 100

How strong the business is, in one number. Last changed 20 Nov 2026.

How the business score works

Profit checks: is the profit real cash?

6 of 8 checks clear

2 of 10 checks could not be run.

Simple checks on the accounts. Which 2 are flagged is in Pro.

How the profit check works

PROHow the score was builtEach part of the score, with the numbers behind it
PROWhich checks were flaggedEvery check, the watch list and the filings behind them
PROFrom the filingsLoan defaults, and money lent or guaranteed to the promoters’ side
PROThe case for and againstA weighted list of what looks good and what looks weak

Key numbers & peers

Grouped by topic. Each number says what period it is for.

Price

Market cap
₹761 Cr
Prev close
₹29.90
52w High
₹42.8
52w Low
₹18.5
Beta
0.5
Price CAGR 1y
29.0%
Price CAGR 3y
56.0%
Price CAGR 5y
—
Price CAGR 10y
—

Valuation

P/E ratioEPS TTM to Sep 2026
26.2
Industry P/E
25.8
P/B ratio
3.9
EV / EBITDA
15.5
Enterprise value
₹1,045 Cr
PEG ratio
0.5
Dividend yield
0.0%

Returns

ROCE
15.2%
ROCE 5y average
15.8%
ROE
16.3%
ROE 3y average
14.0%
ROE last year
16.0%
Return on assets
3.6%

Sales, profit & margins

Annual revenue
₹703 Cr
Annual profit
₹23.4 Cr
EPS
₹1.0
Operating margin
7.3%
Net profit margin
3.3%
EBITDA margin
7.3%
Sales latest quarterSep 2026 quarter
₹217 Cr
Profit latest quarterSep 2026 quarter
₹7.78 Cr
OPM latest quarterSep 2026 quarter
9.5%

Growth a year

Sales growth 3y
15.1%
Sales growth 5y
29.5%
Sales growth TTM
32.0%
Profit growth 3y
47.8%
Profit growth 5y
54.2%
Profit growth TTM
45.4%
YoY quarterly sales growthSep 2026 vs Sep 2025
28.5%
YoY quarterly profit growthSep 2026 vs Sep 2025
101.0%

Balance sheet

Book Value
₹7.7
Face Value
₹1.0
Borrowings
₹285 Cr
Total debt
₹392 Cr
Total cash
₹1.00 Cr
Net debtas of 31 Mar 2026
₹284 Cr
Debt / Equity
2.0
Interest coverage
2.2
Reserves / Equity
5.5

Cash & payout

Operating cash flow
-₹2.00 Cr
Free cash flow
-₹51.1 Cr
FCF yield
-10.1%
Net cash flow
-₹1.00 Cr
Dividend payout
0.0%
Revenue per employeeyear to 31 Mar 2026
₹10.43 Cr

Holdings

Promoter holding
57.8%
FII holding
21.9%
DII holding
—
Public holding
20.2%

Enterprise value, step by step

What buying the whole company would cost: its market value, less the cash it holds over its debt. Net debt from the balance sheet of 31 Mar 2026.

  1. Market cap₹761 Cr
  2. +Net debt₹284 Cr
  3. =Enterprise value₹1,045 Cr

Peers

Peers
CompanyPrice ₹P/EMkt cap ₹ CrDiv yieldProfit qtr ₹ CrProfit changeSales qtr ₹ CrSales changeROCE
Pidilite Industries1,620.0061.51,64,9970.74%626+7.09%4,298+20.91%31.58%
Gujarat Fluorochemicals Limited4,932.7078.354,2600.06%240+34.08%1,760+45.45%9.69%
Navin Fluorine International Limited10,077.0056.451,6950.15%269+81.91%1,191+57.00%21.37%
Aether Industries Limited1,620.3085.321,5060.00%68.0+25.93%347+23.88%11.92%
Deepak Nitrite Limited1,531.2019.520,8860.47%398+234.18%3,076+61.75%11.59%
Fine Organic Industries Limited5,488.5034.916,8280.20%152+39.56%729+22.12%21.47%
Aarti Industries Limited449.5026.916,3050.22%168+58.49%3,669+74.71%6.85%
Sudarshan Pharma Industries Limited29.9026.27610.00%7.78+101.04%217+28.48%15.16%
Medianof the whole group of 79, 20 Nov 202626.40.29%+37.60%+27.01%11.59%

Median: the middle value of the whole peer group of 79 companies. Price and rupee sizes are left blank there, as a middle value of those says little.

Competes with 7 listed companies

Aarti Industries Limited, Aether Industries Limited, Deepak Nitrite Limited, Fine Organic Industries Limited, Gujarat Fluorochemicals Limited, Navin Fluorine International Limited, Pidilite Industries

4 · Balance sheet & cash

Balance sheet

What the company owns and what it owes, at each year end and at the filed half-years. ₹ crore.

Consolidated

At Mar 2026: ₹642 cr of assets, and who funds them

Shareholders’ own money funds 24% of it; borrowings 44%.

What it owns

  • Fixed assets ₹104 cr 16%
  • Being built ₹3.00 cr 0%
  • Everything else ₹535 cr 83%

Who funds it

  • Shareholders’ money ₹155 cr 24%
  • Borrowings ₹285 cr 44%
  • Everything else ₹202 cr 31%

Each year end. Newest year end shaded.

Balance sheet
Line, ₹ croreMar 2020FY20Mar 2021FY21Mar 2022FY22Mar 2023FY23Mar 2024FY24Mar 2025FY25Mar 2026FY26
Equity capital10101024242424
Reserves1013207788107131
Borrowings21303134105171285
Other liabilities1847779767100202
Total funding5899138232283402642
Fixed assets666202648104
Being built (CWIP)00102233
Investments0001214300
Other assetsreceivables, cash, rest5393131200242302534
Total assets5899138232283402642

Cash flows

Real money coming in and going out — from the business, from investments and from loans. ₹ crore.

Consolidated

Pick a period to see where its cash went.

Where the cash went, year to Mar 2026, ₹ crore

In words

  • The business used ₹2.30 cr more than it brought in.
  • It put ₹78.0 cr into assets and investments.
  • It raised ₹79.0 cr from shareholders and lenders.
  • Cash in hand fell by ₹1.00 cr. Free cash flow: −₹50.8 cr.
Cash flow
Line, ₹ croreMar 2020FY20Mar 2021FY21Mar 2022FY22Mar 2023FY23Mar 2024FY24Mar 2025FY25Mar 2026FY26
From the business1.003.00-4.00-29.006.00-32.00-2.30
From investing-3-1-1-26-5-21-78
From financingdividends, buybacks, loans0-1466-125379
Net change in cash-20-111-120-1
Free cash flow-4.001.00-5.00-43.002.00-54.00-50.84
Cash ÷ operating profitbefore tax20.00%43.00%-36.00%-193.00%26.00%-80.00%-4.00%

Free cash flow = cash from the business − spending on assets + what assets sold fetched; the same rule for years and half-years.

Efficiency ratios

How fast customers pay and how well capital earns. Each year, Mar 2020 to Mar 2026.

Consolidated

Debtor days

121 days

Days customers take to pay. Lower is faster.

121 days in FY26, against 116 days in FY25. Over these 7 years: 65 days (FY23) to 121 days (FY26).

Inventory days

129 days

Days stock sits before it is sold.

129 days in FY26, against 117 days in FY25. Over these 7 years: 46 days (FY20) to 129 days (FY26).

Days payable

111 days

Days it takes to pay its suppliers.

111 days in FY26, against 76 days in FY25. Over these 7 years: 40 days (FY20) to 111 days (FY26).

Cash conversion cycle

139 days

Debtor days plus inventory days, less days payable.

139 days in FY26, against 156 days in FY25. Over these 7 years: 46 days (FY22) to 156 days (FY25).

Working capital days

17 days

Days of sales tied up in running the business.

17 days in FY26, against 52 days in FY25. Over these 7 years: 17 days (FY26) to 62 days (FY24).

Return on capital (ROCE)

15%

Operating profit on the capital used.

15% in FY26, against 16% in FY25. Over these 6 years: 14% (FY24) to 19% (FY22).

5 · Owners & payouts

Shareholding pattern

Who owns the company: promoters, foreign funds, Indian funds and the public, at each quarter end. In %.

To 30 Sep 2026

Share of the company held by each group, at each filed quarter end, Mar 2023 to Sep 2026.

Promoters

The group that controls the company

57.81%

Since Mar 2023 +0.42 pts

Foreign funds (FIIs)

Investors outside India

21.94%

Since Mar 2023 +18.36 pts

Public

Individuals and others

20.19%

Since Mar 2023 −18.83 pts

Number of shareholders

Accounts holding the share

1,250

Since Mar 2023 +6

  • Foreign funds raised their share from 3.58% to 21.94%.
  • Promoters held 57.81% at Sep 2026, against 57.39% at Mar 2023.
  • Shareholders grew from 1,244 to 1,250.
Shareholding, % of the company at each quarter end
Holder, %Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoters57.3957.3957.3957.3957.3957.3957.3957.3957.3958.9357.81+0.42
Foreign funds (FIIs)3.581.401.4013.0718.4519.4920.7919.7819.9519.3821.94+18.36
Public39.0241.2041.2129.5424.1623.0721.7622.7922.6121.6520.19−18.83
Government0.000.000.000.000.000.050.050.050.050.050.05+0.05
Shareholders1,2449839137871,2121,3271,3831,4071,3461,2311,250+6

A figure in bold moved by 0.5 points or more from the quarter before. Change = Sep 2026 against Mar 2023, in points.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividend a share, by the year of its ex-date

No dividend on record.

Share of profit paid as dividend

Each year, Mar 2020 to Mar 2026.

Splits, bonuses & buybacks

  • Split or bonus 1:1022 Nov 2024

Big trades by funds and insiders

None listed for this company.

6 · Price & trading

Open interestPRO

Where option traders are positioned on this stock.

7 · Business

About

What the company is, from our own records: where it sits, where its revenue comes from, and where it works.

Sector
Chemicals
Industry
Specialty Chemicals
Symbol
SUDARSHAN
ISIN
INE00TV01023

Sites · 6

  • Mahad Unit IIMahad, Maharashtra
  • Plant 2 - Turbhe UnitTurbhe, Maharashtra
  • Plant 3Gujarat, Gujarat
  • Srigen API FacilityMedchal, Telangana
  • Unit 2Palghar, Maharashtra
  • Wada PlantWada, Maharashtra

Industry numbers

The numbers that matter most in this industry, from the company's own filings and earnings calls. Each one says its period.

Main figures

  • Exports share of revenue3.46%

Brand spend

  • Ad spendFY to Mar 20260.00%

Revenue and margin

  • EBIT marginSep 2026 quarter8.87%

Working capital

  • Days sales outstanding12 months to Sep 2026117 days
  • Customer advancesFY to Mar 2026₹3.89 Cr

Costs

  • Employee costSep 2026 quarter0.94%

Profit quality

  • Other income shareSep 2026 quarter17.89%
  • Interest coverSep 2026 quarter2.04x

Returns

  • RoE12 months to Mar 202616.35%
  • RoA12 months to Mar 20264.48%
  • Sales to net block12 months to Sep 20267.88x

Leverage

  • Net debt to EBITDA12 months to Mar 20265.53x

Growth

  • Revenue growth (YoY)Sep 2026 quarter28.48%

Capex

  • CapexFY to Mar 2026₹48.8 Cr
  • Capex to revenueFY to Mar 20266.95%

How they have moved

EBIT margin · quarterly

Source: Computed from the filings

Sep 268.87%Computed from the filings
Jun 268.31%Computed from the filings
Mar 268.65%Computed from the filings
Dec 255.93%Computed from the filings

Other income share · quarterly

Source: Computed from the filings

Sep 2617.89%Computed from the filings
Jun 2616.27%Computed from the filings
Mar 2626.29%Computed from the filings
Dec 2529.23%Computed from the filings

Interest cover · quarterly

Source: Computed from the filings

Sep 262.04xComputed from the filings
Jun 261.91xComputed from the filings
Mar 263.09xComputed from the filings
Dec 251.83xComputed from the filings

Revenue growth (YoY) · quarterly

Source: Computed from the filings

Sep 2628.48%Computed from the filings
Jun 2620.07%Computed from the filings
Mar 2636.72%Computed from the filings
Dec 2545.26%Computed from the filings

Capex (fiscal year) · yearly

Source: Computed from the filings

FY26₹48.8 CrComputed from the filings
FY25₹22.0 CrComputed from the filings
FY24₹4.00 CrComputed from the filings

Capex to revenue (fiscal year) · yearly

Source: Computed from the filings

FY266.95%Computed from the filings
FY254.36%Computed from the filings
FY240.86%Computed from the filings

Supply chain

Links to other companies, as recorded in our map from filings and announcements. A news event that hits one of them can reach Sudarshan Pharma Industries Limited through this map.

Sells to · 23

  • AFMSDPharmaceutical formulations and medicines
  • Akzo NobelPharmaceutical formulations and specialty chemicals
  • Asian PaintsSpecialty chemicals
  • Astral PipesPharmaceutical formulations and specialty chemicals
  • Bayer AGPharmaceutical formulations and specialty chemicals
  • DuPontPharmaceutical formulations and specialty chemicals
  • IntasPharmaceutical formulations and specialty chemicals
  • Invision Life SciencesPharmaceutical formulations and specialty chemicals
  • Jubilant Life SciencesPharmaceutical products
  • L&T (Aeronautical division)Pharmaceutical formulations and medicines
+ 13 more
  • LupinPharmaceutical products
  • MinovaPharmaceutical formulations and specialty chemicals
  • Muscat Pharmaceuticals Mfg. CoPharmaceuticals and specialty chemicals
  • NikapharmaPharmaceuticals and specialty chemicals
  • Omkar PharmaPharmaceutical formulations and specialty chemicals
  • ReliancePharmaceutical formulations and specialty chemicals
  • RemexPharmaceuticals and specialty chemicals
  • Rose ChemicalsPharmaceuticals and specialty chemicals
  • SRFPharmaceutical formulations and specialty chemicals
  • SandozPharmaceutical products
  • Suan Hong TradingPharmaceuticals and specialty chemicals
  • Sun PharmaPharmaceutical products
  • Teva PharmaPharmaceutical products

Uses as raw material · 1

  • Active Pharmaceutical IngredientsFrom China

Exports to · 8

  • Australia
  • Bangladesh
  • Oman
  • Syria
  • Taiwan
  • United Arab Emirates
  • United Kingdom
  • Uzbekistan

8 · News & documents

News and what it reaches

Filings and news about Sudarshan Pharma Industries Limited, and bigger events that reach it through its owners, rivals, customers or suppliers. Newest first. Open one to see how the effect spreads.

AI-written from public sources · Information, not advice · Not SEBI-registered

Documents

Earnings calls, results presentations and annual reports, straight from the company and the exchanges.

Annual reports · 1

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.